Pharmacoeconomic analysis of classic and alternative eradication therapy regimens for Helicobacter pylori
https://doi.org/10.21518/2079-701X-2019-3-148-151
Abstract
The article presents the results of pharmacoeconomic analysis of classical and alternative schemes of the first line of Helicobacter pylori eradication therapy used in Russian practice. The most profitable from the economic point of view were sequential therapy, quadrotherapy with bismuth drug and hybrid therapy. In turn, from the point of view of clinical and economic balance, such schemes as triple therapy with addition of bismuth drug, as well as quadrotherapy without bismuth drug were the most optimal.
About the Authors
A. M. Veliyev
Federal State Budgetary Educational Institution of Higher Education «Evdokimov Moscow State Medical and Dental University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Applicant of the Department of Propaedeutics of Internal Diseases and Gastroenterology,
127473, Moscow, 20, Delegateskaya St., Moscow, Russia. 1
D. N. Andreyev
Federal State Budgetary Educational Institution of Higher Education «Evdokimov Moscow State Medical and Dental University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Associate Professor of the Department of Pro paedeutics of Internal Diseases and Gastro enterology,
127473, Moscow, 20, Delegateskaya St., Moscow, Russia. 1
E. V. Partsvania-Vinogradova
Federal State Budgetary Educational Institution of Higher Education «Evdokimov Moscow State Medical and Dental University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Postgraduate student of the Department of Propaedeutics of Internal Diseases and Gastroenterology,
127473, Moscow, 20, Delegateskaya St., Moscow, Russia. 1
References
1. Maev I.V., Andreev D.N. Helicobacter pylori infection and associated diseases. M.: Remedium. 2018. (In Russ.)
2. Malfertheiner P., Venerito M., Schulz C. Helicobacter pylori Infection: New Facts in Clinical Management. Curr Treat Options Gastroenterol. 2018 Dec;16(4):605-615.
3. O’Morain N.R., Dore M.P., O’Connor A.J.P., Gisbert J.P., O’Morain C.A. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018 Sep;23(Suppl 1):e12519.
4. Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv. Res. Gastroenterol. Hepatol. 2017;7(2):555710. doi: 10.19080/ARGH.2017.07.555710.
5. Samsonov A.A., Grechushnikov V.B., Andreev D.N., Yureniev G.L., Korovina T.I., Lezhneva Y.A., Maev I.V. Evaluation of pharmacoeconomic indicators of treatment of patients with diseases associated with Helicobacter pylori. Therapeutic archive [Terapevticheskij arhiv]. 2014;8:57-61. (In Russ.)
6. Vorobiev P.A. Clinical and economic analysis. 3-rd edition. M.: «Newdiamed», 2008.: 778 p. (In Russ.)
7. Andreev D.N., Dicheva D.T., Maev I.V. Possibilities of optimization of eradication therapy of Helicobacter pylori infection in modern clinical practice. Therapeutic archive [Terapevticheskij arhiv]. 2017;2:76-83. (In Russ.)
8. Veliyev A.M., Maev I.V., Andreyev D.N., Dicheva D.T., Lobanova E.G., Bektemirova L.G. Efficacy and safety of quadrotherapy without bismuth drugs in treatment of patients with Helicobacter pylori-associated stomach and duodenal ulcer. Therapeutic archive [Terapevticheskij arhiv]. 2019;8: accepted for publishing. (In Russ.)
9. Bordin D.S., Masharova A.A., Homeriki S.G. Chronic gastritis: a modern view of the old problem. Experimental. and clin. gastroenterol [Jeksperiment. i klin. Gastrojenterol.]. 2012;5:99-106. (In Russ.)
10. Andreev D.N., Maev I.V., Dicheva D.T., Samsonov A.A., PartsvaniaVinogradova E.V. Efficacy and safety of rebamipid application in the scheme of triple eradication therapy of infection Helicobacter pylori: prospective randomized comparative study. Therapeutic archive [Terapevticheskij arhiv]. 2018;90(8):27-32. (In Russ.)
11. Andreev D.N., Maev I.V., Kucheryavy Y.A., Dicheva D.T, Partsvania-Vinogradova E.V. Efficacy and safety of anti-Helicobacter therapy in patients with concomitant chronic hepatitis C. Therapeutic archive [Terapevticheskij arhiv].2016;88(4):75- 81. (In Russ.)
12. Yurenev G.L., PartsvaniaVinogradova E.V., Andreev D.N., Dicheva D.T., Maev I.V. Efficacy and safety assessment of the hybrid scheme of eradication therapy of Helicobacter pylori infection. Therapeutic archive [Terapevticheskij arhiv]. 2018;90(8):33- 39. (In Russ.)
Review
For citations:
Veliyev AM, Andreyev DN, Partsvania-Vinogradova EV. Pharmacoeconomic analysis of classic and alternative eradication therapy regimens for Helicobacter pylori. Meditsinskiy sovet = Medical Council. 2019;(3):148-151. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-148-151
Views:
609
Email this article 